Announcements Trials

Browse Landscape

Phase

Phase NA 5 Phase 2 4 Phase 4 1 Phase 3 1

Status

Sponsor Class

OTHER 28 INDUSTRY 20 NETWORK 19 NIH 8 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Uterine Cervical Neoplasms 11 Stomach Neoplasms 11 Carcinoma, Non-Small-Cell Lung 11 Ovarian Neoplasms 8 Neoplasms 8 Esophageal Neoplasms 8 Carcinoma, Ovarian Epithelial 7 Fallopian Tube Neoplasms 6 Colorectal Neoplasms 5 Recurrence 4 Neoplasm Metastasis 4 Multiple Myeloma 4 Mouth Neoplasms 4 Head and Neck Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Colonic Neoplasms 4 Carcinoma, Hepatocellular 4 Rectal Neoplasms 3 Nasopharyngeal Carcinoma 3 Lymphoma, Non-Hodgkin 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Glioblastoma 3 Urinary Bladder Neoplasms 2 Prostatic Neoplasms 2 Polycystic Ovary Syndrome 2 Peripheral Nervous System Diseases 2 Melanoma 2 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2

Interventions

trametinib 1 palbociclib 1 olaparib 1 nilotinib 1 glasdegib 1 futibatinib 1 durvalumab 1 dabrafenib 1 ceritinib 1 capmatinib 1 Lapatinib 1 High-Throughput Nucleotide Sequencing 1 Base Sequence 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × OTHER_GOV × Sarcoma × Clear all

NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡